SynBioBeta Speaker
Christopher Bradley
Matter Bio
CEO
Chris Bradley is a serial entrepreneur with a background in neuroscience, cell biology and computer science. He has dedicated his career to founding and translating breakthrough biotechnology and healthcare technology companies that push the boundaries of what is possible. As part of his entrepreneurial journey, Chris has been involved at the earliest stages of company conception; whiteboarding technological solutions and in-sourcing academic IP, all the way through licensing, fundraising, conference main stage presentations and demos, crafting regulatory strategy, successful patent prosecution and issuing, industry partnerships and business development up to successful sale of his last company to a large multinational corporation. He is currently CEO & Co-Founder of Matter Bio, a DNA repair company. When he’s not obsessing about DNA damage, he can usually be found chasing his condiment covered toddler through the house or working on his 1956 Panhead chopper project.
SynBioBeta 2026 Tickets are Live
Confirmed Speakers
Sessions Featuring
Christopher
This Year
•
-
Longevity
Engineering Longevity: Reprogramming the Foundations of Aging
Aging is increasingly understood as a gradual loss of biological stability. DNA accumulates damage, protein homeostasis collapses, and cells drift away from youthful identities as regulatory networks lose their balance over time. These changes ripple across tissues and organs, driving many of the diseases associated with aging. Today, new tools in synthetic biology, artificial intelligence, and gene editing are revealing how these systems might be stabilized, repaired, or even reset. Researchers are engineering enhanced DNA repair mechanisms inspired by long-lived species, using AI to map the trajectories of cellular aging and uncover rejuvenating interventions, and developing therapies that restore protein metabolism to protect vulnerable tissues such as the brain. This session explores how scientists are moving beyond simply slowing aging to engineering the biological systems that maintain cellular integrity. By targeting the underlying mechanisms that govern genome stability, proteostasis, and cellular identity, researchers are laying the groundwork for a new generation of longevity therapeutics designed to restore function and resilience across the lifespan.
Get a Ticket
•
-
Longevity
Engineering Longevity: Reprogramming the Foundations of Aging
Aging is increasingly understood as a gradual loss of biological stability. DNA accumulates damage, protein homeostasis collapses, and cells drift away from youthful identities as regulatory networks lose their balance over time. These changes ripple across tissues and organs, driving many of the diseases associated with aging. Today, new tools in synthetic biology, artificial intelligence, and gene editing are revealing how these systems might be stabilized, repaired, or even reset. Researchers are engineering enhanced DNA repair mechanisms inspired by long-lived species, using AI to map the trajectories of cellular aging and uncover rejuvenating interventions, and developing therapies that restore protein metabolism to protect vulnerable tissues such as the brain. This session explores how scientists are moving beyond simply slowing aging to engineering the biological systems that maintain cellular integrity. By targeting the underlying mechanisms that govern genome stability, proteostasis, and cellular identity, researchers are laying the groundwork for a new generation of longevity therapeutics designed to restore function and resilience across the lifespan.
Get a Ticket
Session lineup still growing
Get a Ticket
Featuring
Speaker Coming Soon
•
-
Human Health
From Cells to Patients: Solving the Scale Mismatch in Virtual Biology
Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?
Get a Ticket
Featuring
Speaker Coming Soon
